These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29477576)

  • 21. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
    Tahrani AA
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
    [No Abstract]   [Full Text] [Related]  

  • 22. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
    Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
    Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
    Isaacs M; Tonks KT; Greenfield JR
    Intern Med J; 2017 Jun; 47(6):701-704. PubMed ID: 28580740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
    Danne T; Garg S; Peters AL; Buse JB; Mathieu C; Pettus JH; Alexander CM; Battelino T; Ampudia-Blasco FJ; Bode BW; Cariou B; Close KL; Dandona P; Dutta S; Ferrannini E; Fourlanos S; Grunberger G; Heller SR; Henry RR; Kurian MJ; Kushner JA; Oron T; Parkin CG; Pieber TR; Rodbard HW; Schatz D; Skyler JS; Tamborlane WV; Yokote K; Phillip M
    Diabetes Care; 2019 Jun; 42(6):1147-1154. PubMed ID: 30728224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report.
    Yii ESS; Azli AW; Sitaram PN
    J Med Case Rep; 2022 Jan; 16(1):17. PubMed ID: 34983625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction.
    Cavka L; Bencak Ferko U; Pitz N; Trpkovski Z; Lainscak M
    ESC Heart Fail; 2021 Aug; 8(4):2631-2636. PubMed ID: 34102028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature.
    Patoulias D; Imprialos K; Stavropoulos K; Athyros V; Doumas M
    Curr Clin Pharmacol; 2018; 13(4):261-272. PubMed ID: 30084335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
    Bamgboye AO; Oni IO; Collier A
    Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
    Park JH; Seo I; Shim HM; Cho H
    J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 32. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Lamos EM; Hedrington M; Davis SN
    Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature.
    Chacko B; Whitley M; Beckmann U; Murray K; Rowley M
    Anaesth Intensive Care; 2018 Mar; 46(2):215-219. PubMed ID: 29519226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
    Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
    Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
    Biester T; Kordonouri O; Danne T
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():53-61. PubMed ID: 31081591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium glucose co-transporter-2 inhibitor-induced diabetic ketoacidosis following tooth extraction: improving awareness among dental practitioners.
    Yap SD; Hamblin PS; Bach L; Ekinci E; Wong R
    Aust Dent J; 2021 Dec; 66(4):444-447. PubMed ID: 34432892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
    Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
    BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.